Literature DB >> 12055248

A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans.

Lanying Li1, Despina Moshous, Yungui Zhou, Junhua Wang, Gang Xie, Eduardo Salido, Diana Hu, Jean-Pierre de Villartay, Morton J Cowan.   

Abstract

Athabascan SCID (SCIDA) is an autosomal recessive disorder found among Athabascan-speaking Native Americans and is manifested by the absence of both T and B cells (T(-)B(-)NK(+) SCID). We previously mapped the SCIDA gene to a 6.5-cM interval on chromosome 10p. SCIDA fibroblasts were found to have defective coding joint and reduced, but precise signal joint formation during V(D)J recombination. After excluding potential candidate genes, we conducted a combined positional candidate and positional cloning approach leading to the identification of nine novel transcripts in the refined SCIDA region. One of the transcripts showed significant homology with the mouse and yeast SNM1/PSO(2) and was recently reported (Artemis) to be responsible for another T(-)B(-)NK(+) SCID condition (radiation sensitive SCID) in 13 patients of primarily European origin. In our evaluation of this gene, we have identified a unique nonsense mutation in 21 SCIDA patients that is closely correlated to the founder haplotypes that we had previously identified. This nonsense founder mutation results in the truncation of the deduced protein product. The wild-type construct of the primary transcript can effectively complement the defective coding joint and reduced signal joint formation in SCIDA fibroblasts. The above results indicate that this SNM1-like gene (Artemis) is the gene responsible for SCIDA. We also discovered three additional alternative exons and detected at least six alternatively spliced SCIDA variants (SCIDA-V1, 2, 3, 4, 5, and 6) coexisting with the primary transcript in trace amounts. Finally, we found that the SCIDA primary transcript (Artemis) encodes a nuclear protein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055248     DOI: 10.4049/jimmunol.168.12.6323

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Neonatal screening for severe combined immunodeficiency.

Authors:  Jennifer M Puck
Journal:  Curr Opin Pediatr       Date:  2011-12       Impact factor: 2.856

2.  Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles.

Authors:  Jennifer M Puck
Journal:  J Allergy Clin Immunol       Date:  2012-01-29       Impact factor: 10.793

3.  T cell and B Cell immunity can be reconstituted with mismatched hematopoietic stem cell transplantation without alkylator therapy in artemis-deficient mice using anti-natural killer cell antibody and photochemically treated sensitized donor T cells.

Authors:  Tony Z Xiao; Kanal Singh; Elizabeth Dunn; Rageshree Ramachandran; Morton J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-19       Impact factor: 5.742

Review 4.  Non-homologous DNA end joining and alternative pathways to double-strand break repair.

Authors:  Howard H Y Chang; Nicholas R Pannunzio; Noritaka Adachi; Michael R Lieber
Journal:  Nat Rev Mol Cell Biol       Date:  2017-05-17       Impact factor: 94.444

5.  A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining.

Authors:  Mirjam van der Burg; Hanna Ijspeert; Nicole S Verkaik; Tuba Turul; Wouter W Wiegant; Keiko Morotomi-Yano; Pierre-Olivier Mari; Ilhan Tezcan; David J Chen; Malgorzata Z Zdzienicka; Jacques J M van Dongen; Dik C van Gent
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

6.  Successful newborn screening for SCID in the Navajo Nation.

Authors:  Antonia Kwan; Diana Hu; Miran Song; Heidi Gomes; Denise R Brown; Trudy Bourque; Diana Gonzalez-Espinosa; Zhili Lin; Morton J Cowan; Jennifer M Puck
Journal:  Clin Immunol       Date:  2015-03-08       Impact factor: 3.969

7.  Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency.

Authors:  Kerstin Felgentreff; Yu Nee Lee; Francesco Frugoni; Likun Du; Mirjam van der Burg; Silvia Giliani; Ilhan Tezcan; Ismail Reisli; Ester Mejstrikova; Jean-Pierre de Villartay; Barry P Sleckman; John Manis; Luigi D Notarangelo
Journal:  J Allergy Clin Immunol       Date:  2015-04-25       Impact factor: 10.793

8.  Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems.

Authors:  Thomas R Bauer; Rima L Adler; Dennis D Hickstein
Journal:  ILAR J       Date:  2009

9.  Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs.

Authors:  Linda M Griffith; Morton J Cowan; Donald B Kohn; Luigi D Notarangelo; Jennifer M Puck; Kirk R Schultz; Rebecca H Buckley; Mary Eapen; Naynesh R Kamani; Richard J O'Reilly; Robertson Parkman; Chaim M Roifman; Kathleen E Sullivan; Alexandra H Filipovich; Thomas A Fleisher; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2008-11-06       Impact factor: 10.793

10.  ARTEMIS stabilizes the genome and modulates proliferative responses in multipotent mesenchymal cells.

Authors:  Sarah A Maas; Nina M Donghia; Kathleen Tompkins; Oded Foreman; Kevin D Mills
Journal:  BMC Biol       Date:  2010-10-27       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.